

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-64. (CANCELED)

65. (NEW) An isolated chimeric lyssavirus glycoprotein encoded by a recombinant polynucleotide, wherein said recombinant polynucleotide comprises:

a) a polynucleotide encoding the site III polypeptide of the glycoprotein from genotype GT1 Pasteur virus, wherein said polynucleotide does not encode the entire lyssavirus glycoprotein of said virus, and

b) a polynucleotide encoding the site II polypeptide sequence of the glycoprotein from genotype GT5 lyssavirus, wherein said polynucleotide further comprises a polynucleotide encoding the transmembrane domain and the cytoplasmic domain of the glycoprotein of said genotype GT1 Pasteur virus.

66. (NEW) An immunogenic composition comprising the chimeric lyssavirus glycoprotein of claim 65 and at least one of an adjuvant, excipient, stabilizer, supra molecular vector, or antigen.

67. (NEW) The immunogenic composition of claim 66, wherein said composition induces humoral and cellular immunity.

68. (NEW) The immunogenic composition of claim 66, wherein said immunogenic composition induces a protective immune response.

69. (NEW) The isolated chimeric lyssavirus glycoprotein of claim 65, wherein said glycoprotein further comprises a heterologous peptide, polypeptide, or protein other

than a lyssavirus glycoprotein or a peptide or polypeptide fragment of a lyssavirus glycoprotein.

70. (NEW) The isolated chimeric lyssavirus glycoprotein of claim 69, wherein the heterologous peptide, polypeptide, or protein is a B cell epitope, a CD8 cell epitope, or both.

71. (NEW) An isolated chimeric lyssavirus glycoprotein encoded by a recombinant polynucleotide encoding said chimeric lyssavirus glycoprotein, wherein said recombinant polynucleotide comprises:

a) a polynucleotide encoding the site III polypeptide of the glycoprotein from genotype GT1 Pasteur virus, wherein said polynucleotide does not encode the entire lyssavirus glycoprotein of said virus,

b) a polynucleotide encoding the site II polypeptide sequence of the glycoprotein from genotype GT5 lyssavirus,

c) a polynucleotide encoding a transmembrane domain of a transmembrane protein; and

d) a polynucleotide encoding a cytoplasmic domain of a glycoprotein.

72. (NEW) The isolated chimeric lyssavirus glycoprotein of claim 71, wherein said glycoprotein further comprises a heterologous peptide, polypeptide, or protein other than a lyssavirus glycoprotein or a peptide or polypeptide fragment of a lyssavirus glycoprotein.

73. (NEW) The isolated chimeric lyssavirus glycoprotein of claim 72, wherein the heterologous peptide, polypeptide, or protein is a B cell epitope, a CD8 cell epitope, or both.

74. (NEW) An isolated chimeric lyssavirus glycoprotein encoded by a recombinant polynucleotide, wherein said recombinant polynucleotide comprises:

a) a polynucleotide encoding the site III polypeptide of the glycoprotein from genotype GT1 lyssavirus, wherein said polynucleotide does not encode the entire lyssavirus glycoprotein of said virus, and

b) a polynucleotide encoding the site II polypeptide sequence of the glycoprotein from genotype GT5 lyssavirus, wherein said polynucleotide further comprises a polynucleotide encoding the transmembrane domain and the cytoplasmic domain of the glycoprotein of said genotype GT1 lyssavirus.

75. (NEW) An immunogenic composition comprising the chimeric lyssavirus glycoprotein of claim 74 and at least one of an adjuvant, excipient, stabilizer, supra molecular vector, or antigen.

76. (NEW) The immunogenic composition of claim 75, wherein said composition induces humoral and cellular immunity.

77. (NEW) The immunogenic composition of claim 75, wherein said immunogenic composition induces a protective immune response.

78. (NEW) The isolated chimeric lyssavirus glycoprotein of claim 74, wherein said glycoprotein further comprises a heterologous peptide, polypeptide, or protein other than a lyssavirus glycoprotein or a peptide or polypeptide fragment of a lyssavirus glycoprotein.

79. (NEW) The isolated chimeric lyssavirus glycoprotein of claim 78, wherein the heterologous peptide, polypeptide, or protein is a B cell epitope, a CD8 cell epitope, or both.